Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to -$14.8 million.

  • Collegium Pharmaceutical's Cash from Financing Activities fell 10994.31% to -$14.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$129.7 million, marking a year-over-year decrease of 4882.16%. This contributed to the annual value of -$60.6 million for FY2024, which is 5676.71% up from last year.
  • According to the latest figures from Q3 2025, Collegium Pharmaceutical's Cash from Financing Activities is -$14.8 million, which was down 10994.31% from -$48.4 million recorded in Q2 2025.
  • In the past 5 years, Collegium Pharmaceutical's Cash from Financing Activities ranged from a high of $517.8 million in Q1 2022 and a low of -$114.2 million during Q2 2024
  • For the 5-year period, Collegium Pharmaceutical's Cash from Financing Activities averaged around $3.1 million, with its median value being -$26.5 million (2021).
  • As far as peak fluctuations go, Collegium Pharmaceutical's Cash from Financing Activities plummeted by 24264.29% in 2021, and later skyrocketed by 461485.87% in 2022.
  • Over the past 5 years, Collegium Pharmaceutical's Cash from Financing Activities (Quarter) stood at -$42.5 million in 2021, then surged by 39.24% to -$25.8 million in 2022, then plummeted by 162.66% to -$67.8 million in 2023, then surged by 39.14% to -$41.3 million in 2024, then surged by 64.1% to -$14.8 million in 2025.
  • Its last three reported values are -$14.8 million in Q3 2025, -$48.4 million for Q2 2025, and -$25.2 million during Q1 2025.